Recent Updates — RDHL
RedHill Biopharma has regained all ex-North America rights to its proprietary drug candidate RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA that terminated their License & Development Agreement on October 15, 2026. As part of the termination, Hyloris paid RedHill a one-time break-up fee of $200,000. The company retains full worldwide rights to RHB-102, an extended-release ondansetron formulation for oncology support and GI indications, including GLP-1/GIP-associated intolerance, and will continue late-stage development while exploring potential partnerships. RedHill Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal disorders and cancer supportive care.
The National Cancer Institute awarded a five-year, $2.9 million grant to the University of Oklahoma to conduct Phase 1b and Phase 2 clinical trials evaluating the combination of opaganib and CAR T-cell therapy for ultra-high-risk multiple myeloma. The funding supports safety and dosage assessments in up to 18 patients, followed by an effectiveness study enrolling up to 21 additional participants. RedHill will supply the investigational drug, while Lentigen Technology provides manufacturing support. RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology.
The company filed a prospectus supplement to raise the maximum aggregate offering amount of American Depositary Shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on February 3, 2025. This administrative update expands the shelf for future equity sales but does not specify a new dollar cap or immediate issuance in this filing. RedHill Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and infectious diseases.
The Nasdaq Stock Market notified RedHill Biopharma that it has been granted an additional 180 calendar day period, extending until April 5, 2027, to regain compliance with the minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This extension follows a prior notification on April 8, 2026, which cited 30 consecutive business days where the closing bid price of the company's American Depositary Shares (ADSs) fell below the threshold. The initial compliance period was set to expire on October 5, 2026. To regain compliance before the new deadline, the ADS closing bid price must remain at or above $1.00 for a minimum of 10 consecutive business days. The company states it meets all other continued listing requirements and that this notification has no immediate effect on trading under the symbol "RDHL." RedHill Biopharma operates in the biotechnology industry, focusing on the development and commercialization of pharmaceutical products.
RedHill Biopharma completed the sale of its 70% stake in Talicia Holdings to Apotex on August 27, 2026, receiving an $18.0 million upfront payment and up to $35.0 million in potential sales milestones. Concurrently, it entered a License and Commercial Supply Agreement with Ferring Pharmaceuticals for exclusive global rights to Rebyota and U.S. rights to Clenpiq, paying $12 million upfront plus royalties and contingent payments. These transactions resulted in stockholders' equity exceeding $5 million as of September 30, 2026. The company operates in the biopharmaceutical industry.
RedHill Biopharma reported a net loss of $6.1 million for the first half of 2026 and raised approximately $5.4 million in net proceeds from a June private placement with Armistice Capital, which included pre-funded warrants and Series A-1/A-2 warrants exercisable into ADSs. The company completed a strategic portfolio reset by selling its 70% stake in Talicia Holdings Inc. for an $18 million upfront payment and acquiring exclusive global commercialization rights to Rebyota and Clenpiq from Ferring Pharmaceuticals for a $12 million upfront fee, funded by the divestment proceeds. These transactions strengthen RedHill's liquidity position as it transitions to a leaner commercial model focused on gastrointestinal therapies and late-stage R&D programs including opaganib and RHB-204. The company operates in the specialty biopharmaceutical industry, developing and commercializing drugs for gastrointestinal diseases, infectious diseases, and oncology.